Gothenburg, Sweden, April 22, 2016. Immunicum AB (publ), pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced that the Chinese Patent Office (SIPO) intends to grant a patent relating to the Company's cancer immune primer, INTUVAX.
- We are pleased with the positive news from the Chinese Patent Office, SIPO, which will further strengthen the protection for our main product. This is especially important since we have an ongoing clinical phase I/II trial with INTUVAX in liver cancer, an indication that is widely spread in China, says Jamal El-Mosleh, CEO of Immunicum.
The Chinese patent to be granted, with the titel "Improved composition for inhibiting tumor cell proliferation", relates to allogeneic dendritic cells (DCs), stimulated by a specific cocktail, for use in the treatment of cancer by intratumoral injection of the DCs.
For further information, please contact:
Jamal El-Mosleh, CEO, Immunicum
Phone: +46 (0) 31 41 50 52
jamal.el-mosleh@immunicum.com
The Company's Certified Adviser is Redeye AB
Phone: +46 (0) 8 545 013 31. www.redeye.se
About INTUVAX
INTUVAX is a cancer immune primer, developed for the treatment of solid tumors. Its active ingredient is activated white blood cells, so called dendritic cells, derived from healthy blood donors. Intratumoral injection of these cells is expected to lead to an inflammatory response which in turn leads to tumor-specific activation of the patient's cytotoxic T lymphocytes.
About Immunicum AB (publ)
Immunicum AB (publ) develops cancer immune primers for the treatment of tumor diseases. A phase II clinical trial for the Company's most advanced product - INTUVAX® against kidney cancer - has been initiated. The project portfolio contains additional clinical phase I/II studies in liver cancer and in gastrointestinal stromal tumors (GIST).